LOS ANGELES--(BUSINESS WIRE)--Lundin Law PC, a shareholder rights firm, announces that it is investigating claims against Lion Biotechnologies, Inc. (“Lion” or the “Company”) (Nasdaq: LBIO) concerning possible violations of federal securities laws.
To get more information about this investigation, please contact Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or by email at email@example.com.
The investigation concerns whether Lion and certain of its officers and/or directors violated federal securities laws. On April 10, 2017, the U.S. Securities and Exchange Commission found that between September 2013 and March 2014, the Company through its former CEO Manish Singh, mislead investors by commissioning over 10 internet publications and 20 widely distributed emails promoting Lion to potential investors that purported to be independent from the company when, they were actually paid promotions.
Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.